Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Pfizer’s maternal RSV vaccine candidate backed by FDA advisory committee

Up to 80,000 children aged under five are hospitalised each year in the US due to RSV infection

- PMLiVE

Crick Institute announces new molecular glue discovery to treat different diseases

The £11.2m research investment includes funds from AstraZeneca and the EPSRC

- PMLiVE

Working together to achieve better patient pathways

Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated

Design-thinking. Iterating for continuous improvement.

How design can lead improvement within Pharma

Mednet

Bayer symbol

Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer

More than 47,000 new cases of prostate cancer are diagnosed every year in England

- PMLiVE

AbbVie and Genmab’s blood cancer therapy granted FDA accelerated approval

Approximately 150,000 new cases of DLBCL are diagnosed globally each year

- PMLiVE

UK Biobank study to review human ageing over time moves into second stage

Over 60,000 volunteers to have second whole-body scans for imaging research study

- PMLiVE

Researchers at ICR London discover new nutrient source for cancer growth

Study reveals new findings of dietary changes within pancreatic cancer cells

Steph’s Story

Associate Medical Writer, Steph talks about her experiences with Generalised Anxiety Disorder and Panic Attacks

Mednet

Mario’s Story

Senior Designer, Mario talks about struggling with Generalised Anxiety Disorder, Social Anxiety Disorder resulting in mild OCD

Mednet

- PMLiVE

Our Work With Mind

In celebration of Mental Health Awareness Week 2023, we're sharing some of our recent work with Mind.

Mednet

- PMLiVE

AstraZeneca’s heart failure treatment recommended by NICE for expanded use

More than 550,000 patients have a confirmed heart failure diagnosis in England alone

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links